Celularity Inc. (CELU)

Market Cap	57.96M
Revenue (ttm)	54.22M
Net Income (ttm)	-57.89M
Shares Out	23.95M
EPS (ttm)	-2.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,072
Open	2.290
Previous Close	2.290
Day's Range	2.250 - 2.470
52-Week Range	1.001 - 5.220
Beta	0.61
Analysts	n/a
Price Target	n/a
Earnings Date	May 8, 2025

About CELU

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBankin. Its lead therapeutic programs include CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 123
• Stock Exchange: NASDAQ
• Ticker Symbol: CELU
• Website: https://www.celularity.com

Financial Performance

In 2024, Celularity's revenue was $54.22 million, an increase of 138.11% compared to the previous year's $22.77 million. Losses were -$57.89 million, -70.51% less than in 2023.